Patients who have had chemotherapy, targeted small molecule therapy, or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier\r\n* Note: patients with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had a prior monoclonal antibody, chemotherapy, or targeted small molecule therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier (alopecia is an exception)\r\n* Note: Subjects with =< grade  neuropathy or ototoxicity are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Participants who have had chemotherapy, targeted small molecule therapy or study therapy within  days of protocol treatment, or those who have not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier; subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent;\r\n* NOTE: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Concurrent somatostatin analog therapy is allowed (for control of hormone excess) provided patient has been on stable dose for at least two months and tumor progression has been documented
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Participants who have had chemotherapy, targeted small molecule therapy or study therapy within  days of protocol treatment, or those who have not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier; subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy =<  days prior to registration or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously\r\nadministered agent\r\n* NOTE: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Participants who have had chemotherapy, targeted small molecule therapy or study therapy within  days of protocol treatment, or those who have not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier; subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
COHORT : Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks or growth factors within  week prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study.\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
COHORT : Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks or growth factors within  week prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to cycle  day  or who has not recovered (i.e. =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Receipt of the last dose or treatment of anti-cancer chemotherapy, radiotherapy, surgery, endocrine therapy, targeted therapy, biologic therapy, or tumor embolization =<  weeks ( weeks for any monoclonal antibody (mAb),  weeks for nitrosoureas or mitomycin C) prior to first dose of study treatment, or has not recovered (i.e., to =< grade  or Baseline) from clinically significant adverse events (AEs) due to these previously administered agents\r\n* Note: patients with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: subjects with other irreversible toxicity (e.g., hearing loss) or reversible toxicity (e.g. alopecia) that is not reasonably expected to be exacerbated by the investigational product and is not expected to interfere with study participation may be included\r\n* Note: if patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Participants who have had chemotherapy, targeted small molecule therapy, or radiotherapy within  weeks prior to study day  ( weeks for nitrosoureas or mitomycin C) or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to previously administered agents; Note: subjects with =< grade  peripheral neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Patients with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
Patients are not eligible who have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to registration or who have not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy other than pre-specified allowed agents, or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy within  weeks prior to study day  or who has not recovered (i.e. =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: subjects with =< grade  neuropathy or chemotherapy-induced alopecia are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has received treatment with chemotherapy, targeted small molecule therapy, or radiation therapy to non-liver sites within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent administered more than  weeks earlier\r\n* Subjects with =< grade  neuropathy or alopecia are an exception to this criterion and may qualify for the study\r\n* If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent and meeting the criteria for organ function; patients who receive palliative radiation therapy within  week prior to day  are allowed; patients on treatment with targeted therapy (like EGFR or ALK TKIs) may start study treatment  days from last treatment; NOTE: subjects with =< grade  neuropathy or other clinically insignificant adverse events (AEs) as determined by the PI are an exception to this criterion and may qualify for the study following adequate pre-study documentation; NOTE: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study registration or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study
Prior chemotherapy or radiation therapy =<  days prior to registration or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Note: patients with =< grade  neuropathy are an exception to this criterion and may qualify for the study; Note: if a patient underwent major surgery, s/he must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study Day  or who has not recovered (i.e., =< Grade  or at baseline) from adverse events due to a previously administered agent.\r\n* Note: Subjects with =< Grade  neuropathy are an exception to this criterion and may qualify for the study.\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
Has received prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n*Note: subjects with =< grade  neuropathy due to chemotherapy are an exception to this criterion and may qualify for the study\r\n*Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has not recovered from prior surgery, chemotherapy or radiation therapy from adverse events due to a previous treatment/ administered agent (i.e., ? grade  or return to baseline prior to treatment)\r\n* Note: Subjects with ? grade  neuropathy, any grade hearing loss or tinnitus, or typical side effects from radiotherapy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Concurrent somatostatin analog therapy is allowed (for control of hormone excess) provided patient has been on stable dose for at least two months and tumor progression has been documented
Participants must not have had prior chemotherapy, targeted small molecule therapy, radiation or other anti-cancer therapy (with exceptions for disease-specific hormone treatments considered standard of care) within  weeks prior to study day  or have not recovered (i.e. =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had a prior chemotherapy, immunotherapy, biological therapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to previously administered agent\r\n* Note: subjects with =< grade  neuropathy, alopecia or hypothyroidism are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy events due to a previously administered agent
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, a minimum of four weeks must have passed and they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with ? grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study at the discretion of the treating provider\r\n* Note: If subject received major surgery, they must have recovered adequately, in the opinion of the treating provider, from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent.\r\n* Note: Subjects with =< grade  neuropathy or alopecia are an exception to this criterion.\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention as determined by the investigators prior to starting therapy.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  days prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study with principal investigator (PI) approval\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to Cycle/ Day  or who has not recovered (i.e., ? Grade  or at baseline) from adverse events due to a previously administered agent(s). Note: Patients with ? Grade  neuropathy are an exception to this criterion and may qualify for the trial. Note: If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: Subjects with =< grade  hematologic toxicities are an exception to this criterion and may qualify for the study\r\n* Note: Subjects with =< grade  fatigue are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  days prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent. - Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study. - Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Toxicity that has not recovered to =< grade  is allowed if it meets the inclusion requirements for laboratory parameters
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Prior chemotherapy, targeted small molecule therapy within  weeks prior to study day  or not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy or =< grade  alopecia are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent. Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
Prior chemotherapy, targeted small molecule therapy, or radiation therapy =<  weeks prior to registration or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery or radiation, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: anti-estrogen therapy must be stopped prior to study day 
Had prior chemotherapy, targeted small molecule therapy within  weeks, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from AEs due to a previously administered agent \r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if a subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: patients who have received >  Gy to the thorax must have completed this radiation  months prior to enrollment in the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  days prior to registration or who has not recovered (i.e., =< grade  or at baseline) from AEs due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n** Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or to baseline) from adverse events due to a previously administered agent\r\n* NOTE: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: if subject received major surgery, they must have recovered adequately from surgery prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; patients receiving hormone manipulation (e.g. tamoxifen, aromatase inhibitors, LHRH agonist, etc.) for reasons other than treatment of metastatic breast cancer may continue this treatment at the discretion of the investigator
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: subjects with =< grade  hypertension managed with medication are an exception to this criterion and may qualify for the study\r\n* Note: subjects with =< grade  endocrinopathy (e.g. hypothyroidism or adrenal insufficiency managed with medication) are an exception to this criterion and may qualify for the study
Participants treated with prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to the prior chemotherapy, targeted small molecule therapy, and radiation therapy\r\n* Note: Subjects with =< grade  neuropathy and/or alopecia are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have had the surgery >  weeks prior to study day  and recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade ); Note: Patients with =< grade  neuropathy or =< grade  alopecia are an exception to this criterion and may qualify for the study; Note: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Participants who have had chemotherapy, targeted small molecule therapy or study therapy within  days of protocol treatment, or those who have not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier; subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study Day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent. Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Prior chemotherapy, radiotherapy, biological cancer therapy, targeted small molecule therapy or major surgery within  days prior to study day  or who has not recovered (i.e., to CTCAE =< grade  or at baseline) from adverse events due to previously administered therapy, Note: subjects with =< grade  neuropathy and alopecia are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion\r\nand may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiotherapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to the first dose of study drug or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; patients with =< grade  neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; patients must be  weeks out from major procedures
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy who has not recovered (i.e., =< grade  or at baseline level) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, radiation, or targeted small molecule therapy, within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent;\r\n* Note: Subjects with alopecia or =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Lesions that have been selected for HDCRT may have been previously radiated provided:\r\n** The tumor site that was previously radiated has progressed.\r\n** A baseline biopsy of the tumor site is obtained following progression and prior to study entry\r\n* Note: Subjects currently receiving androgen deprivation therapy or hormonal therapy are allowed\r\n* Note: Subjects receiving nitrosoureas within  weeks prior to study day  are excluded
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with ? Grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n- Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n- Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; patients must be  weeks out from major procedures and  weeks out from minor procedures
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered small molecule agent; a. Note: subjects with =< grade  neuropathy or alopecia are an exception to this criterion and may qualify for the study; b. Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: participants with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy and, has to be at least  days after the surgery
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; prior radiotherapy to the liver is not allowed\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent \r\n* Note: subjects with grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Patients who have had chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day - or who have not recovered (to =< grade  or baseline) from adverse events due to a previously administered agent are not eligible\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and do qualify for the study\r\n* Note: if subject received major surgery within  weeks prior to day -, they must have recovered adequately from the toxicity and/or complications per principal investigator (PI) discretion
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy or with hematologic toxicity that has recovered to levels above that stated in inclusion criterion are an exception to this criterion and may qualify for the study if all other inclusion/exclusion criteria are met\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention (i.e., =< grade  or at baseline) prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has received prior chemotherapy, targeted small molecule therapy, or radiation therapy for the current gynecologic malignancy\r\n* Note: subjects who have received treatment for a prior unrelated malignancy must have recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (ie, =< grade  or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previous treatment\r\n* Note: subjects with permanent =< grade  toxicities (e.g. neuropathy) or toxicities corrected through routine medical management (e.g. thyroid replacement for hypothyroidism) are an exception to this criterion and may qualify for the study\r\n** Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n*** Note: subjects with asymptomatic =< grade  laboratory or dermatologic abnormalities are an exception to this criterion and may qualify for the study pending the judgment of the treating radiation oncologist
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy or targeted small molecule therapy within  weeks prior to administration of the study drug or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; *Note: Subjects with permanent =< grade  toxicities (e.g. neuropathy) or toxicities corrected through routine medical management (e.g. thyroid replacement for hypothyroidism), are an exception to this criterion and may qualify for the study; *Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; *Note: Subjects with =< grade  amylase or lipase elevations abnormalities that have no corresponding clinical manifestations (e.g. manifestation of pancreatitis), are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy or targeted small molecule therapy within  weeks prior to study treatment or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; previous radiation to extracranial sites may be completed at any time prior to initiation of pembrolizumab;\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Toxicity that has not recovered to =< grade  is allowed if it meets the inclusion requirements for laboratory parameters
Has had prior chemotherapy, targeted small molecule therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade  neuropathy or =< grade  alopecia are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, or targeted small molecule therapy, within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention in the opinion of the principal investigator prior to starting therapy
Has had prior chemotherapy within  weeks, or targeted small molecule therapy or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: subjects with any grade alopecia are an exception to this criterion and may qualify for the study
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to the first dose of MK- or has not recovered (i.e., to =< grade  or baseline) from adverse events due to a previously administered agent; Note, subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; Note, if a subject received major surgery, she must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, radiation or other anti-cancer therapy (with exceptions for certain disease-specific hormone and other treatments) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks ( weeks for nitrosureas or mitomycin C) prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy and be at least  days from surgery
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to lymphodepletion or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy, alopecia, hypophysitis stable on physiologic dose of steroid equivalent to prednisone <  mg/day, hypothyroidism stable on hormone replacement are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy or targeted small molecule therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Subject has had prior chemotherapy, targeted small molecule therapy,  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; note: subjects with =< grade  neuropathy are an exception to this criterion
Has had prior chemotherapy, targeted small molecule therapy, within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; prior radiation does not require a washout period; note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy or targeted small molecule therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with alopecia or =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to day  drug administration on study or inability to recover (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy or alopecia are exceptions to this criterion and may qualify for the study\r\n* Note: If subject had major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Subject has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent;\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Patient who has had chemotherapy, radioactive, or biological cancer therapy within four weeks prior to the first dose of study drug, or who has not recovered to CTCAE grade  or better from the AEs due to cancer therapeutics administered more than four weeks earlier; subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: toxicity that has not recovered to =< grade  is allowed if it meets the inclusion requirements for laboratory parameters defined in the inclusion criterion above
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy to the lung or brain within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; previous radiation to other sites may be completed at any time prior to initiation of MK-\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: toxicity that has not recovered to =< grade  is allowed if it meets the inclusion requirements for laboratory parameters
Has had chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to Study Day  or who has not recovered (i.e., ? Grade  or at baseline) from adverse events due to a previously administered agent NOTE: Subjects with ? Grade  neuropathy or Grade  alopecia are an exception to this criterion and may qualify for the study. Investigators should discuss individual cases with the Medical Monitor or Sponsor as needed; or
Has not recovered from prior surgery, chemotherapy or radiation therapy from adverse events due to a previous treatment/administered agent (i.e., =< grade  or return to baseline prior to treatment)\r\n* Note: subjects with =< grade  neuropathy, any grade hearing loss or tinnitus, or typical side effects from radiotherapy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; Note: If the subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with ? grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Subjects with ? grade  neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent. Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study. Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent. Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy or targeted small molecule therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; note: subjects with =< grade  neuropathy or alopecia are an exception to this criterion and may qualify for the study; note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Prior chemotherapy, targeted small molecule therapy, or radiation therapy =<  weeks prior to registration or who has not recovered to =< grade  or baseline from adverse events due to the previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n*Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n*Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks of the first protocol treatment or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: Patients who have had prior treatments with tyrosine kinase inhibitors (e.g. Tarceva) require only a -hour washout period prior to starting protocol treatment
Patients who have had chemotherapy, targeted small molecule therapy, or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier\r\n* Note: patients with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy and/or alopecia are exceptions to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Any patient who has not recovered (i.e., =< grade  or at baseline) from adverse events or complications due to a previously administered systemic agent, radiation therapy, or major surgery\r\n* Exceptions: \r\n** Subjects with =< grade  neuropathy, hot flashes, or hypertension may qualify for the study if all other eligibility criteria met\r\n** Other toxicity or complications that are deemed by the treating investigator as not clinically significant (e.g., urinary incontinence from past prostatectomy)
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior monoclonal antibody, chemotherapy (including dexamethasone for multiple myeloma [MM] treatment), targeted small molecule therapy, or radiation therapy within  weeks prior to transplant admission (or ~ weeks prior to the first dose of MK-); OR has not recovered (i.e. =< grade  or at baseline) from adverse events due to a previously administered agent more than  weeks prior to transplant admission or more than  weeks prior to the first dose of MK-; NOTE: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; NOTE: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to transplant admission; NOTE: Toxicity that has not recovered to =< grade  is allowed if it meets the requirements per institutional guidelines for high-dose melphalan and autologous transplant
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks ( weeks for measurable sites of CNS disease) prior to study Day  or not recovered from adverse events (improved to grade  or less) due to a previously administered agent\r\n* Note: Subjects with neuropathy or =< grade  alopecia are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Patients may continue on ovarian suppression
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\nNote: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or has not recovered (i.e. =< grade  or at baseline) from AEs due to a previously administered agent\r\n* Note: Patients with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If patient received major surgery, she must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: If participant underwent major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Participants with alopecia are an exception to this criterion
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to receipt of study medication or who has not recovered (i.e., =< grade  or at baseline; excludes alopecia and grade  neuropathy) from adverse events due to a previously administered agent\r\n* If subject had major surgery, they must have recovered adequately from the toxicity and complications from the intervention prior to starting therapy
Has had prior chemotherapy or targeted small molecule therapy within  weeks prior to study day  or who has not recovered (i.e., >= grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from AEs due to a previously administered agent; Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Received prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study registration or who has not recovered (i.e., ? Grade  or at baseline) from adverse events from previously administered agents. NOTE: Subjects with ? Grade  neuropathy are an exception to this criterion and can still be considered for the study.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; Note: subjects with alopecia, =< grade  neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to radiation therapy or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: prior radiation therapy does not necessary exclude patients; the index lesion may be acceptable for stereotactic radiosurgery (SRS) and this will be determined by radiation oncologist\r\n* Note: if there is more than one symptomatic lesion, patients will be excluded if the lesions cant be encompassed within one radiation portal\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Had prior chemotherapy, targeted small molecule therapy within  weeks, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from AEs due to a previously administered agent - Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study - Note: if a subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy -\r\n Note: patients who have received >  Gy to the thorax must have completed this radiation  months prior to enrollment in the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n*Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy and/or alopecia are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Patients who have had chemotherapy or targeted small molecule therapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier\r\n* Note: patients with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; NOTE: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; NOTE: if subject received major surgery, s/he must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with =< grade  neuropathy or typical side effects from radiotherapy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  (except lenvatinib for patients in cohort ) or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: \r\n** Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n** If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to registration, as deemed by treating investigator or site PI
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy and alopecia are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must wait >=  weeks prior to starting study treatment, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade  neuropathy and alopecia are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must wait >=  weeks prior to starting study treatment; they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; patients who previously received RT in any form would not be eligible\r\n* Note: Subjects with =< grade  neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent; note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; note: toxicities that specifically define eligibility for this protocol (nephropathy, otopathy, neuropathy, or other as allowed by principal investigator [PI]) are exceptions